CORCEPT THERAPEUTICS I

Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian Cancer

06 May 2021 16:01:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

29 Apr 2021 16:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Initiates Phase 1b Trial of Relacorilant Plus Pembrolizumab (Keytruda®) in Patients with Adrenal Cancer with Cortisol Excess

15 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Expands Executive Team; Atabak Mokari Joins As Chief Financial Officer; Charles Robb Named Chief Business Officer

01 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results

23 Feb 2021 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

08 Feb 2021 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call

01 Feb 2021 16:05:00 By Nasdaq GlobeNewswire